These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 17019704

  • 1. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V, Pace J, Chisum K, Rosowsky A.
    Proteins; 2006 Dec 01; 65(4):959-69. PubMed ID: 17019704
    [Abstract] [Full Text] [Related]

  • 2. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
    Cody V, Galitsky N, Luft JR, Pangborn W, Queener SF, Gangjee A.
    Acta Crystallogr D Biol Crystallogr; 2002 Sep 01; 58(Pt 9):1393-9. PubMed ID: 12198294
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
    Cody V, Luft JR, Pangborn W, Gangjee A, Queener SF.
    Acta Crystallogr D Biol Crystallogr; 2004 Apr 01; 60(Pt 4):646-55. PubMed ID: 15039552
    [Abstract] [Full Text] [Related]

  • 5. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A, Guo X, Queener SF, Cody V, Galitsky N, Luft JR, Pangborn W.
    J Med Chem; 1998 Apr 09; 41(8):1263-71. PubMed ID: 9548816
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity correlations for three pyrido[2,3-d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase.
    Cody V, Pace J, Namjoshi OA, Gangjee A.
    Acta Crystallogr F Struct Biol Commun; 2015 Jun 09; 71(Pt 6):799-803. PubMed ID: 26057816
    [Abstract] [Full Text] [Related]

  • 7. Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5'-(ω-carboxyalkoxy)benzyl]pyrido[2,3-d]pyrimidine derivatives.
    Cody V, Pace J.
    Acta Crystallogr D Biol Crystallogr; 2011 Jan 09; 67(Pt 1):1-7. PubMed ID: 21206056
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH.
    Cody V, Luft JR, Pangborn W.
    Acta Crystallogr D Biol Crystallogr; 2005 Feb 09; 61(Pt 2):147-55. PubMed ID: 15681865
    [Abstract] [Full Text] [Related]

  • 11. Correlations of inhibitor kinetics for Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes.
    Cody V, Pace J, Makin J, Piraino J, Queener SF, Rosowsky A.
    Biochemistry; 2009 Mar 03; 48(8):1702-11. PubMed ID: 19196009
    [Abstract] [Full Text] [Related]

  • 12. Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
    Forsch RA, Queener SF, Rosowsky A.
    Bioorg Med Chem Lett; 2004 Apr 05; 14(7):1811-5. PubMed ID: 15026078
    [Abstract] [Full Text] [Related]

  • 13. Structure-based enzyme inhibitor design: modeling studies and crystal structure analysis of Pneumocystis carinii dihydrofolate reductase ternary complex with PT653 and NADPH.
    Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Queener SF.
    Acta Crystallogr D Biol Crystallogr; 2002 Jun 05; 58(Pt 6 Pt 2):946-54. PubMed ID: 12037296
    [Abstract] [Full Text] [Related]

  • 14. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A, Forsch RA, Sibley CH, Inderlied CB, Queener SF.
    J Med Chem; 2004 Mar 11; 47(6):1475-86. PubMed ID: 14998335
    [Abstract] [Full Text] [Related]

  • 15. Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.
    Cody V, Pace J, Rosowsky A.
    Acta Crystallogr D Biol Crystallogr; 2008 Sep 11; 64(Pt 9):977-84. PubMed ID: 18703847
    [Abstract] [Full Text] [Related]

  • 16. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523.
    Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL.
    Biochemistry; 1997 Nov 11; 36(45):13897-903. PubMed ID: 9374868
    [Abstract] [Full Text] [Related]

  • 17. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A, Vasudevan A, Queener SF.
    J Med Chem; 1997 Sep 12; 40(19):3032-9. PubMed ID: 9301665
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A, Forsch RA, Queener SF.
    J Med Chem; 2003 Apr 24; 46(9):1726-36. PubMed ID: 12699390
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.